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INTRODUCTION: The poor prognosis associated with Glioblastoma multiforme (GBM) is 
multifactorial but includes the capacity of residual tumour cells not removed by surgery and 
resistant to radio-/chemo-therapy undergoing diffuse invasion into the surrounding brain 
tissue. Caveolin-1 (Cav-1) is the major structural and functional component of caveolae. In a 
number of tumour types Cav-1 is recognised to participate in cytoskeletal rearrangement, 
integrin-mediated adhesion and/or matrix remodelling. We proposed Cav-1 serves to promote 
invasion of GBM cells. To investigate this we have employed in an in-vitro 3D cellular 
invasion assay.  
 
METHOD: The human GBM cell lines, UP007 and UP029 established from primary cultures 
of biopsy-derived brain tumours (University of Portsmouth), U-87 MG (ECACC) and U-373 
MG (ECACC) were genetically modified to stably knock-out Cav-1 using a Lentiviral Cav-1 
shRNA approach; corresponding stably transfected non-target (NT) shRNA cell lines were 
generated as controls. Neuropheres were formed and embedded within an extracellular matrix 
(Matrigel™). Over a two-/four-day period (depending on cell line) the migration of cells 
away from the neurophere core (CORE) was quantified by image capture and processing 
(Image J) using a custom-developed MatLab script for pixel density analysis indicative of the 
density of migrating cellular material.  
 
RESULTS: Cav-1 knockout resulted in significant (P0.05) towards reduced invasion. 
Depending upon the cell line the Cav-1 knockdown also resulted in reduced size and cellular 
density of the neurosphere core (UP007 and UP029) indicative of reduced prolif- Abstracts 
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CONCLUSION: Using an in-vitro 3D cellular invasion assay we have found Cav-1 
expression in a series of three GBM cell lines to promote cellular invasion capacity. Ongoing 
studies are addressing signalling mechanisms and the influence of the microenvironment.  
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